Xencor, Inc. (XNCR) News
Filter XNCR News Items
XNCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest XNCR News From Around the Web
Below are the latest news stories about XENCOR INC that investors may wish to consider to help them evaluate XNCR as an investment opportunity.
All You Need to Know About Xencor (XNCR) Rating Upgrade to BuyXencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Xencor to Participate at Upcoming Investor ConferencesPASADENA, Calif., November 26, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences: |
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden CrossWhen a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react? |
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%Market forces rained on the parade of Xencor, Inc. ( NASDAQ:XNCR ) shareholders today, when the analysts downgraded... |
Xencor (XNCR) Reports Q3 Loss, Tops Revenue EstimatesXencor (XNCR) delivered earnings and revenue surprises of 27.55% and 38.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Xencor: Q3 Earnings SnapshotPASADENA, Calif. AP) — Xencor Inc. XNCR) on Wednesday reported a loss of $45.1 million in its third quarter. |
Xencor Reports Third Quarter 2024 Financial ResultsPASADENA, Calif., November 06, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates. |
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel DiseasePASADENA, Calif., November 04, 2024--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025. |